ENSEMBLE, known for being a single dose vaccine, showed efficacy in 72% of 43,783 recipients who participated in Phase 3 trials.
“Our goal has always been to create a simple and effective solution for as many people as possible and have the maximum impact to help end the pandemic,” said CEO Alex Gorsky.
Of the participants, there were 468 symptomatic cases of COVID-19. These individuals were reviewed 14 to 28 days after being injected.
“Don’t let the perfect get in the way of good enough,” tweeted Kizzmekia Corbett, one of the developers of the vaccine for Moderna, on Friday, encouraged by ENSEMBLE’s efficacy percentages.
1 / n: People are asking me for comments, and I’ll tell you how my former project manager used to tell me about me overcoming and striving for “perfection” in some things … “Don’t let the perfect get in the way of good enough. “This is damn good for 1 dose …” in a pandemic “.– KizzyPhD (@KizzyPhD) January 29, 2021
The data showed that, from the 14th day, and culminating 28 full days after vaccination, the recipients were 66% protected against moderate to severe complications of COVID-19, so that even if someone caught the virus within 28 days after receiving this vaccine, the effects would not be serious, 66% of the time.
cnxps.cmd.push (function () {cnxps ({playerId: ’36af7c51-0caf-4741-9824-2c941fc6c17b’}). render (‘4c4d856e0e6f4e3d808bbc1715e132f6’);});
if (window.location.pathname.indexOf (“656089”)! = -1) {console.log (“hedva connatix”); document.getElementsByClassName (“divConnatix”)[0].style.display = “none”;}
The ad notes that “the results of the ENSEMBLE study include efficacy against emerging strains of coronavirus, including some highly infectious variants present in the US, Latin America and South Africa”.
The vaccine’s effectiveness rate dropped significantly in the United States, where it was 72%, to 57% in South Africa, where a new variant was recently discovered, causing global concern. Concerns about the spread of the South African strain contributed to the recent closure of Ben-Gurion Airport.
“The potential to significantly reduce the burden of serious illness by providing an effective and well-tolerated vaccine with just one immunization is a critical component of the global public health response,” said Paul Stoffels, scientific director at Johnson & Johnson.
The vaccine is, according to the data, 85% effective in general in preventing serious complications that can result in hospitalizations.
The company noted that it will monitor test participants for “up to two years”.